What patients must know when taking medication! Adverse reactions of tremelimumab

Tremelimumab/Tremelimumab is a monoclonal antibody checkpoint inhibitor used in combination with a second checkpoint inhibitor, durvalumab, to treat unresectable hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC). The combination of tremelimumab and durvalumab is associated with a relatively high rate of serum aminotransferase elevations during treatment and a significant rate of clinically apparent immune-mediated liver injury, which may be severe or even fatal.

Warnings and precautions related to tremelimumab include immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrine disorders, cutaneous reactions, nephritis, and pancreatitis), infusion-related reactions, and embryo-fetal toxicity. Common adverse reactions include rash, diarrhea, fatigue, pruritus, musculoskeletal pain, and abdominal pain. Common laboratory abnormalities include elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), decreased hemoglobin, decreased sodium, increased bilirubin, increased alkaline phosphatase, and lymphopenia.

Tremelimumab/Tremelimumab is a new type of cancer immunotherapy drug. It has not yet been launched in China, so it cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. It is understood that the US version of temsitumumab original drug sold overseas may cost more than more than 3,000 US dollars per box, and the specification is 300mg/50mL (20mg/mL). The price is still relatively expensive. At present, we are not aware of the production and release of generic drugs of temsitumumab. For specific overseas prices and drug details, please consult Yaode Medical Consultants.